RU2016110546A - Комбинированная лекарственная терапия - Google Patents

Комбинированная лекарственная терапия Download PDF

Info

Publication number
RU2016110546A
RU2016110546A RU2016110546A RU2016110546A RU2016110546A RU 2016110546 A RU2016110546 A RU 2016110546A RU 2016110546 A RU2016110546 A RU 2016110546A RU 2016110546 A RU2016110546 A RU 2016110546A RU 2016110546 A RU2016110546 A RU 2016110546A
Authority
RU
Russia
Prior art keywords
cancer
combination
methyl
solvate
trifluoromethyl
Prior art date
Application number
RU2016110546A
Other languages
English (en)
Russian (ru)
Other versions
RU2016110546A3 (enExample
Inventor
Джоэл ГРЕШОК
Кертис Эрл БАХМЭН
Сэмюэл Чарльз БЛЭКМЭН
Original Assignee
ГЛАКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛАКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛАКСОСМИТКЛАЙН ЭлЭлСи
Publication of RU2016110546A publication Critical patent/RU2016110546A/ru
Publication of RU2016110546A3 publication Critical patent/RU2016110546A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2016110546A 2013-09-19 2014-09-16 Комбинированная лекарственная терапия RU2016110546A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361879895P 2013-09-19 2013-09-19
US61/879,895 2013-09-19
PCT/US2014/055816 WO2015042029A1 (en) 2013-09-19 2014-09-16 Combination drug therapy

Publications (2)

Publication Number Publication Date
RU2016110546A true RU2016110546A (ru) 2017-10-24
RU2016110546A3 RU2016110546A3 (enExample) 2018-03-20

Family

ID=52689320

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016110546A RU2016110546A (ru) 2013-09-19 2014-09-16 Комбинированная лекарственная терапия

Country Status (10)

Country Link
US (1) US20160228446A1 (enExample)
EP (1) EP3046556A4 (enExample)
JP (3) JP6346944B2 (enExample)
KR (1) KR20160055911A (enExample)
CN (1) CN105530934A (enExample)
AU (1) AU2014321456B2 (enExample)
BR (1) BR112016005000A8 (enExample)
CA (1) CA2921156A1 (enExample)
RU (1) RU2016110546A (enExample)
WO (1) WO2015042029A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6346944B2 (ja) * 2013-09-19 2018-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法
US10206949B2 (en) 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US20210393651A1 (en) * 2018-11-09 2021-12-23 Dana-Farber Cancer Institute, Inc. Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
NZ564223A (en) * 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
AU2007212447B2 (en) * 2006-02-03 2013-02-21 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
BRPI0709771B1 (pt) * 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
RU2554081C2 (ru) * 2010-02-24 2015-06-27 Медивэйшн Простейт Терапьютикс, Инк. Способ синтеза соединений диарилтиогидантоина и диарилгидантоина
KR101594002B1 (ko) * 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
US20150342957A1 (en) * 2013-01-09 2015-12-03 Glaxosmithkline Intellectual Property (No.2) Limited Combination
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
JP6346944B2 (ja) * 2013-09-19 2018-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法

Also Published As

Publication number Publication date
JP6563558B2 (ja) 2019-08-21
AU2014321456A1 (en) 2016-03-10
CN105530934A (zh) 2016-04-27
AU2014321456B2 (en) 2018-05-24
WO2015042029A1 (en) 2015-03-26
JP6346944B2 (ja) 2018-06-20
JP2019196391A (ja) 2019-11-14
JP2016530208A (ja) 2016-09-29
RU2016110546A3 (enExample) 2018-03-20
US20160228446A1 (en) 2016-08-11
EP3046556A4 (en) 2017-04-26
CA2921156A1 (en) 2015-03-26
BR112016005000A8 (pt) 2018-01-23
KR20160055911A (ko) 2016-05-18
EP3046556A1 (en) 2016-07-27
JP2018158930A (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
KR101673731B1 (ko) 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
ES2613931T3 (es) Compuestos peptídicos para tratar el estado epiléptico refractario
ES2745471T3 (es) Formulaciones orales de liberación inmediata para quinazolinonas sustituidas
JP2009102342A5 (enExample)
ES3037078T3 (en) Isoxazoline compounds for use in treating demodicosis
ES2437346T3 (es) Procedimiento para la producción de derivado de diamina
JP2012516900A5 (enExample)
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
JP2013510123A5 (enExample)
JP2016528162A (ja) がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
JP2015535247A5 (enExample)
RU2006130000A (ru) Органические соединения
RU2016116789A (ru) Комбинация энзалутамида и афурезертиба для лечения рака
JP2009539994A5 (enExample)
RU2011150619A (ru) Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения
JP2015517523A5 (enExample)
RU2015140611A (ru) Коньюгат бензофуранона и индола или азаиндола, его получение и применения
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
ES2856204T3 (es) Compuestos de ciclohexenilo, composiciones que los comprenden y usos de los mismos
JP2010514734A (ja) 腸障害の治療のためのイソソルビドモノニトレート誘導体
CA2914742A1 (en) Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception
BR112012020377B1 (pt) Uso de um composto ou sal farmaceuticamente aceitável do mesmo e embalagem comercial
AU2020337892B2 (en) Methods of treatment using BCN057 and BCN512

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190926